Artefill is a permanent injectable wrinkle filler, for the correction of smile lines. Artefill was approved by the U.S. Food and Drug Administration (FDA) as a medical device in October 2006. A prior version of the product called Artecoll has been marketed in Canada and Europe since the 1990s.
Artecoll is a gel suspension of 20% polymethylmethacrylate (PMMA) 30- to 42-micron microspheres, 3.5% collagen derived from cows, and 0.3% lidocaine. [1] [2] The PMMA microspheres in Artecoll are not absorbed by the body and therefore provide a permanent scaffold into which the person's own soft tissue can grow; the PMMA microspheres can only be removed by cutting them out. [3]
Artecoll is a permanent injectable wrinkle filler used by dermatologists and plastic surgeons to fill smile lines. [1] The initial correction lasts about six months, until the bovine collagen degrades, but as the recipient's tissue grows in, filling may last for about five years [2] and there have been reports of ten years' duration. [3]
Side effects may include lumpiness at the injection site, persistent swelling or redness, increased sensitivity, and rash or itching more than 48 hours after injection. [1] The lumpiness (nodules), and granulomas, can be difficult for doctors to treat. [4]
If the recipient has allergies to bovine collagen or lidocaine, severe allergies, a susceptibility to form keloid or hypertrophic scars, or fails a small skin test, Artefill should not be used. [1] Because the device ultimately works by causing tissue to grow around the microsphere scaffold, there is a risk of overgrowth if too much Artefill is administered. [5]
The product was invented by German plastic surgeon Gottfried Lemperle and the first version was called Arteplast and clinical trials started in 1989. An unacceptable rate of complications led to a new formulation, Artecoll, for which the Dutch company Rofil Medical received European marketing approval in 1994 and for which Canderm Pharma received Canadian approval in 1996. [6] Artes Medical Inc. was formed in the US in 1999 by Lemperle and his two sons to bring the technology to the U.S. and secure FDA approval. [6] [7]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link). is a gel suspension of 20% polymethylmethacrylate homogeneous 30- to 42-μm microspheres in 3.5% bovine collagen solution mixed with 0.3% lidocaine that may have durability over 5 years."
Artefill is a permanent injectable wrinkle filler, for the correction of smile lines. Artefill was approved by the U.S. Food and Drug Administration (FDA) as a medical device in October 2006. A prior version of the product called Artecoll has been marketed in Canada and Europe since the 1990s.
Artecoll is a gel suspension of 20% polymethylmethacrylate (PMMA) 30- to 42-micron microspheres, 3.5% collagen derived from cows, and 0.3% lidocaine. [1] [2] The PMMA microspheres in Artecoll are not absorbed by the body and therefore provide a permanent scaffold into which the person's own soft tissue can grow; the PMMA microspheres can only be removed by cutting them out. [3]
Artecoll is a permanent injectable wrinkle filler used by dermatologists and plastic surgeons to fill smile lines. [1] The initial correction lasts about six months, until the bovine collagen degrades, but as the recipient's tissue grows in, filling may last for about five years [2] and there have been reports of ten years' duration. [3]
Side effects may include lumpiness at the injection site, persistent swelling or redness, increased sensitivity, and rash or itching more than 48 hours after injection. [1] The lumpiness (nodules), and granulomas, can be difficult for doctors to treat. [4]
If the recipient has allergies to bovine collagen or lidocaine, severe allergies, a susceptibility to form keloid or hypertrophic scars, or fails a small skin test, Artefill should not be used. [1] Because the device ultimately works by causing tissue to grow around the microsphere scaffold, there is a risk of overgrowth if too much Artefill is administered. [5]
The product was invented by German plastic surgeon Gottfried Lemperle and the first version was called Arteplast and clinical trials started in 1989. An unacceptable rate of complications led to a new formulation, Artecoll, for which the Dutch company Rofil Medical received European marketing approval in 1994 and for which Canderm Pharma received Canadian approval in 1996. [6] Artes Medical Inc. was formed in the US in 1999 by Lemperle and his two sons to bring the technology to the U.S. and secure FDA approval. [6] [7]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link). is a gel suspension of 20% polymethylmethacrylate homogeneous 30- to 42-μm microspheres in 3.5% bovine collagen solution mixed with 0.3% lidocaine that may have durability over 5 years."